Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Orchid Pharma Ltd.

NSE: ORCHPHARMA | BSE:524372

₹1134.35 2.85 (0.25%) 1D

Pharmaceuticals & Biotechnology

Buy Sell

Open an Account with Bigul in 5 minutes

Performance

Today’s low

1114.60

Today’s High

1145.00

52W low

432.00

52W High

1360.00

Open Price

1145.00

Prev. Close

1064.5500

Volume

32929.00

Value

37353011.15

Fundamentals

Market Cap Cr

5753.30

Price to Earnings

62.80

Price to Book Value

4.90

Dividend Yield

0.00

PE to Growth

0.60

Op Revenue TTM Cr

819.37

Net Profit TTM Cr

91.60

Cash From Operating Activity Cr

125.99

Return on Equity %

7.88

EMA & SMA

Bullish Moving Averages

11

Bearish Moving Averages

5

5Day EMA

1141.4

10Day EMA

1141.4

12Day EMA

1138.3

20Day EMA

1123

26Day EMA

1113.5

50Day EMA

1088.1

100Day EMA

1027.5

200Day EMA

897.1

5Day SMA

1138.7

10Day SMA

1158.7

20Day SMA

1121

30Day SMA

1086.4

50Day SMA

1075.1

100Day SMA

1084.4

150Day SMA

959.6

200Day SMA

847.8

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

04 Jul, 2024

60.1

Week

58.5

Month

66.5

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

1131.30

PIVOT

First Resistance

1148.05

Second Resistance

1161.75

Third Resistance

1178.50

First Support

1117.60

Second Support

1100.85

Third Support

1087.15

Relative Strength Index

53.88

Money Flow Index

62.8

MACD

24.73

MACD Signal

26.87

Average True Range

54.6

Average Directional Index

20.81

Rate of Change (21)

18.22

Rate of Change (125)

55.03

Commodity Channel Index

10.4

Williams %R

-59.1

BETA

1 Month

0.79

3 Month

0.74

1 Year

0.47

3 Year

0.28

PRICE CHANGE ANALYSIS

↓ -2.75%

1 Week

Low

High

1114.55

1193.2

↑ 18.22%

1 Month

Low

High

936.8

1260

↑ 0.38%

3 Months

Low

High

913.25

1260

↑ 55.01%

6 Months

Low

High

702.75

1359.95

↑ 129.42%

1 Year

Low

High

432.05

1359.95

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 229.99 228.03 206.94 184.81 211.63 168.69 171.09 133.92 181.98 161.66 123.67
Operating Expenses Qtr 188.18 184.68 175.06 160.78 170.21 146.10 147.43 118.54 150.76 143.40 114.46
Operating Profit Qtr 28.92 35.92 23.70 22.14 39.69 13.66 17.82 12.45 29.48 15.89 7.44
EBIDT Qtr Cr 41.81 43.35 31.88 24.03 79.57 22.59 23.66 15.38 29.30 18.01 61.95
Depreciation Qtr 8.40 9.27 7.84 7.71 7.21 8.18 17.76 21.63 26.63 20.22 20.06
Net Profit Qtr 33.19 30.55 20.24 10.78 64.87 6.73 -3.32 -14.09 -1.78 -8.99 31.99
Basic EPS Qtr 6.86 6.42 4.40 2.64 15.89 1.65 -0.81 -3.45 -0.44 -2.20 7.84
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 849.76 685.33 565.98 457.17 529.94
Operating Expenses Annual Cr 708.69 582.28 499.72 392.81 549.71
Operating Profit Annual 110.68 83.62 57.26 57.89 -44.26
Operating Profit Margin Annual % 13.02 12.20 10.12 12.66 -8.35
Total Expenses Annual Cr 758.23 669.29 618.75 553.04 679.77
EBIDT Annual Cr 141.07 103.05 66.26 64.36 -19.78
EBIDT Annual margin % 16.60 15.04 11.71 14.08 -3.73
Depreciation 33.22 54.79 32.01 108.90 125.90
PAT Before ExtraOrdinary Items Annual Cr 94.75 55.25 -52.77 -95.87 -149.84
Net Profit Annual 94.75 54.19 -4.81 -117.15 -149.84
Basic EPS Annual 19.59 13.28 -1.18 -28.70 -16.87
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 1218.32 731.96 677.95 681.34 1056.20
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 124.21 164.67 222.40 442.26 516.48
Total Current Liabilities Annual Cr 209.67 326.63 193.83 100.87 139.06
Total Capital Plus Liabilities Annual Cr 1552.20 1223.26 1094.19 1224.47 1711.74
Fixed Assets Annual 640.22 619.15 593.44 677.82 1127.33
Total Non Current Assets Annual 769.91 729.46 658.88 682.22 1129.08
Total Current Assets Annual 782.29 493.79 435.31 542.25 582.67
Total Assets Annual 1552.20 1223.26 1094.19 1224.47 1711.74
Contingent Liabilities plus Commitments Annual Cr - 44.91 24.87 45.31 0.97
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 130.73 13.39 89.57 24.36 80.42
Cash from Investing Activity Annual -315.81 -26.70 112.93 67.21 167.12
Cash from Financing Annual Activity 167.07 31.17 -216.80 -164.99 -250.33
Net Cash Flow Annual -18.01 17.86 -14.30 -73.42 -2.79
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 240.21 179.33 166.10 166.93 258.77
ROE Annual % 7.77 7.40 -0.70 -17.19 -14.18
ROCE Annual % 8.03 5.38 3.80 -3.96 -9.26
Total Debt to Total Equity Annual 0.11 0.45 0.40 0.63 0.47
EBDIT Annual Margin % 17.21 15.47 11.89 14.28 -3.91
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 230.46 228.21 207.11 184.81 211.63 168.69 171.09 133.92 179.88 163.74 129.50
Operating Expenses Qtr 188.18 185.20 175.44 160.78 170.21 146.10 147.43 118.54 153.47 147.31 116.43
Operating Profit Qtr 28.92 35.39 23.31 22.14 39.69 13.66 17.82 12.45 24.67 14.07 11.31
EBIDT Qtr Cr 42.28 43.01 31.67 24.03 73.85 22.59 23.66 15.38 24.49 13.14 79.36
Depreciation Qtr 8.42 9.27 7.84 7.71 7.21 8.18 17.76 21.63 26.62 20.22 20.07
Net Profit Qtr 32.96 29.43 19.80 9.40 59.14 7.59 -5.39 -15.01 -6.59 -13.86 49.40
Basic EPS Qtr 6.81 6.18 4.30 1.85 14.49 1.86 -1.32 -3.68 -1.61 -3.40 12.10
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 850.23 685.33 568.56 465.29 532.53
Operating Expenses Annual Cr 708.69 582.28 506.42 400.28 533.52
Operating Profit Annual 110.67 83.62 53.13 49.78 -25.48
Operating Profit Margin Annual % 13.02 12.20 9.35 10.70 -4.78
Total Expenses Annual Cr 758.29 669.29 625.46 560.53 663.60
EBIDT Annual Cr 141.54 103.05 62.14 65.00 -0.99
EBIDT Annual margin % 16.65 15.04 10.93 13.97 -0.19
Depreciation 33.24 54.79 87.02 108.92 125.92
PAT Before ExtraOrdinary Items Annual Cr 95.06 55.25 -56.90 -95.25 -131.07
Net Profit Annual 92.17 46.32 -1.95 -116.53 -131.07
Basic EPS Annual 19.06 11.35 -0.48 -28.55 -14.75
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 1169.47 688.65 647.38 652.91 1024.36
Minority Interest Liability Annual Cr 0.00 0.00 0.00 0.00 0.00
Total Non Current Liabilities Annual Cr 124.43 164.67 222.40 442.26 516.48
Total Current Liabilities Annual Cr 259.97 371.89 240.78 142.08 180.82
Total Capital Plus Liabilities Annual Cr 1553.87 1225.21 1110.56 1237.25 1721.66
Fixed Assets Annual 650.24 619.56 593.49 677.88 1127.41
Total Non Current Assets Annual 763.12 724.20 660.68 687.39 1134.44
Total Current Assets Annual 790.75 501.01 449.89 549.86 587.22
Total Assets Annual 1553.87 1225.21 1110.56 1237.25 1721.66
Contingent Liabilities plus Commitments Annual Cr - 48.71 24.87 0.19 0.97
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 125.99 18.34 92.47 23.59 80.80
Cash from Investing Activity Annual -312.03 -31.21 112.94 67.21 167.11
Cash from Financing Annual Activity 167.04 31.17 -216.80 -164.99 -250.33
Net Cash Flow Annual -19.00 18.29 -11.39 -74.20 -2.42
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 230.58 168.72 158.61 159.96 250.97
ROE Annual % 7.88 6.72 -0.30 -17.84 -12.79
ROCE Annual % 8.37 5.65 -2.86 -4.00 -8.23
Total Debt to Total Equity Annual 0.11 0.48 0.41 0.66 0.49
EBDIT Annual Margin % 17.27 15.47 11.10 14.44 -0.19
Name Holding Percent Holding Id Pledged % Locked %
Name Holding Percent Holding Id Pledged % Locked %
Dhanuka Laboratories Limited 69.84 75279073 0 0
Name Holding Percent Holding Id
QUANT MUTUAL FUND-QUANT VALUE FUND, QUANT MULTI ASSET FUND, QUANT SMALL CAP FUND 6.83 75279076
INVESCO INDIA CONTRA FUND & INVESCO INDIA SMALLCAP FUND ALONG WITH OTHER 4 NAMES 3.97 75279077
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND 1.43 75279078
CARNELIAN STRUCTURAL SHIFT FUND 1.22 75279081
Name Holding Percent Holding Id
Trusts 0.54 75279086
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Sep 13, 2012 3 FINAL - Equity Share
Jul 19, 2011 3 FINAL - Equity Share
Jul 12, 2010 10 FINAL - Equity Share
Sep 17, 2009 1 FINAL - Equity Share
Sep 18, 2008 3 FINAL - Equity Share
Jul 12, 2007 3 FINAL - Equity Share
May 30, 2006 3 FINAL - Equity Share
Jul 13, 2005 4 FINAL - Equity Share
Jul 15, 2004 4 FINAL - Equity Share
Jul 17, 2003 4 FINAL - Equity Share
Jul 16, 2002 - FINAL - Equity Share
Jun 29, 2001 - FINAL - Equity Share
Ex-Date Split Ratio Record Date
Ex-Date Purpose Notes
May 23, 2024 Audited Results -
Feb 08, 2024 Quarterly Results -
Nov 04, 2023 Quarterly Results -
Aug 10, 2023 Quarterly Results -
May 10, 2023 Audited Results -
Feb 09, 2023 Quarterly Results -
Dec 01, 2022 Others Inter alia, to consider and approve, amongst other things, raising of funds and issuance of securities through Qualified Institutions Placement basis.
Nov 14, 2022 Quarterly Results -
Aug 10, 2022 Quarterly Results -
May 12, 2022 Audited Results -
Feb 12, 2022 Quarterly Results -
Nov 14, 2021 Quarterly Results -
Aug 13, 2021 Quarterly Results -
Jul 15, 2021 Others inter-alia, to consider and approve: Fund raising by way of issuance of equity shares through preferential allotment/private placement in single/multiple tranches.
May 22, 2021 Audited Results -
Feb 09, 2021 Quarterly Results -
Nov 11, 2020 Quarterly Results -
Sep 07, 2020 Quarterly Results -
Jun 29, 2020 Audited Results -
Feb 17, 2020 Quarterly Results -
Nov 14, 2019 Quarterly Results -
Aug 12, 2019 Quarterly Results -
Jun 03, 2019 Audited Results (Revised)
May 31, 2019 Audited Results -
Feb 13, 2019 Quarterly Results -
Jan 29, 2019 Quarterly Results -
Nov 30, 2018 Quarterly Results By Resolution Professional
Aug 21, 2018 Audited Results -
Apr 17, 2018 Quarterly Results for the month of December 31, 2017
Mar 16, 2018 Quarterly Results for fthe month of Sep' 2017
Mar 05, 2018 Quarterly Results for fthe month of June' 2017
May 26, 2017 Audited Results -
Feb 07, 2017 Quarterly Results -
Nov 09, 2016 Quarterly Results -
Aug 13, 2016 Quarterly Results & Others -
May 27, 2016 Audited Results -
Feb 10, 2016 Quarterly Results -
Nov 09, 2015 Quarterly Results -
Aug 13, 2015 Quarterly Results -
May 28, 2015 Audited Results -
Mar 30, 2015 Appointment of Women Director -
Feb 13, 2015 Quarterly Results -
Nov 13, 2014 Quarterly Results -
Aug 14, 2014 Quarterly Results -
Jul 14, 2014 Preferential Issue of shares -
May 12, 2014 Quarterly Results -
Feb 11, 2014 Quarterly Results -
Nov 29, 2013 Audited Results For 18 months ended september 2013.i.e from April 012012 to september 30.2013
Aug 14, 2013 Quarterly Results -
May 15, 2013 Quarterly Results -
Feb 13, 2013 Quarterly Results -
Nov 09, 2012 Quarterly Results -
Aug 14, 2012 Quarterly Results -
May 14, 2012 Audited Results & Dividend -
Feb 08, 2012 Quarterly Results -
Jan 07, 2012 To consider the Merger To consider the proposal for Merger of its wholly owned subsidiary, Orchid Research Laboratories Ltd. with Orchid Chemicals & Pharmaceuticals Ltd.
Nov 01, 2011 Quarterly Results -
Jul 29, 2011 Quarterly Results -
May 18, 2011 Audited Results & Dividend -
Jan 19, 2011 Quarterly Results -
Oct 28, 2010 Quarterly Results -
Jul 21, 2010 Quarterly Results -
May 27, 2010 Audited Results & Dividend -
Apr 28, 2010 Appointment of Executive Director The Board has appointed Mr. S. Krishnan, Head - Finance & Business Planning as Executive Director of the Company w.e.f. April 28, 2010.
Jan 29, 2010 Quarterly Results -
Dec 15, 2009 Others To sale & transfer of its generic injectables pharmaceuticals business to Hospira, Inc., USA. The acquisition by Hospira includes Orchid's beta-lactam antibiotics manufacturing complex.
Oct 30, 2009 Quarterly Results -
Jul 31, 2009 Quarterly Results -
Jun 29, 2009 Audited Results & Dividend -
Jan 28, 2009 Quarterly Results -
Oct 30, 2008 Quarterly Results -
Jul 30, 2008 Quarterly Results -
May 29, 2008 Audited Results & Dividend -
Jan 17, 2008 Quarterly Results -
Oct 18, 2007 Quarterly Results -
Jul 19, 2007 Quarterly Results -
May 03, 2007 Audited Results & Dividend -
Jan 19, 2007 To consider issue of warrants Issue of 5 million Warrants, convertible into Equity Shares to the Promoter(s) / Promoter Group(s) / Relatives of Promoters.
Oct 19, 2006 Quarterly Results -
Jul 27, 2006 Quarterly Results -
Apr 28, 2006 Accounts & Dividend -
Jan 19, 2006 Quarterly Results -
Dec 23, 2005 Allotment of 19649 equity shares Have allotted 19649 equity shares of Rs 10 each to the employees under ESOP 1999 scheme.
Nov 02, 2005 Allotment of GDR's Has allotted 8,650,000 Global Depositary Receipts at a price of US$ 4.34 per GDR (equivalent to Rs 195 per share), each GDR representing one underlying equity share of Company.
Oct 13, 2005 Quarterly Results -
Jul 18, 2005 Quarterly Results -
Jun 15, 2005 Issue of GDRs In order to meet the further financial outlay on multi-therapeutic expansion and to reduce the interest burden, the Company proposes to raise long term funds by way of issue of GDRs.
Apr 27, 2005 Dividend & Accounts -
Jan 20, 2005 Quarterly Results -
Oct 20, 2004 Quarterly Results -
Jul 28, 2004 Quarterly Results -
Apr 25, 2004 Dividend & Accounts -
Mar 16, 2004 Others To consider raising of long term funds by way of issue of appropriate securities including FCCBs and also issue of warrants to the promoters and associates.
Jan 15, 2004 Quarterly Results -
Oct 31, 2003 Quarterly Results -
Jul 24, 2003 Quarterly Results -
Apr 28, 2003 Dividend & Accounts -
Jan 27, 2003 Quarterly Results -
Dec 16, 2002 Others Acquisition opportunities in the formulations business
Oct 29, 2002 Quarterly Results & Half Yearly Results -
Jul 29, 2002 Quarterly Results -
May 29, 2002 Accounts & Dividend -
Mar 14, 2002 Interim Dividend (Revised)
Jan 30, 2002 Quarterly Results -
Oct 31, 2001 Half Yearly Results & Quarterly Results -
Jul 26, 2001 Quarterly Results -
May 11, 2001 Dividend & Accounts -
Jan 29, 2001 Quarterly Results -
Jan 19, 2001 Others Issue of US $ 30 million Foreign Currency Convertible Bonds (US $ 20 million convertible into equity shares within 18months from date of subscription and US $ 10 million optionally convertible in
Oct 31, 2000 Quarterly Results -
Jul 27, 2000 Quarterly Results -
Jul 18, 2000 Quarterly Results -
May 11, 2000 Accounts -
Apr 14, 2000 Interim dividend -
Jan 27, 2000 Quarterly Results -
Dec 09, 1999 Others Allot of shares to M/s Gazal Indl. Holding Ltd. and M/s. Rights on time ltd
Oct 21, 1999 Quarterly Results -
Jul 29, 1999 Quarterly Results -
May 12, 1999 Accounts & Dividend (Revised) -
Jan 28, 1999 Quarterly Results -
Oct 30, 1998 Quarterly Results -
Jul 10, 1998 Quaterly Results -
May 06, 1998 Accounts & Dividend -
Oct 22, 1997 Half Yearly Results -
Apr 25, 1997 Annual Accounts -
Ex-Date Bonus Ratio Record Date
Sep 15, 2005 1:2 2005-09-17
Bigul
01 Jul 2024

Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India

 The rise came following Orchid Pharma's announcement of a collaboration with pharmaceutical giant Cipla to introduce the antibiotic Cefepime-Enmetazobactam in India
Bigul
28 Jun 2024

Orchid Pharma ties up with Cipla for new UTI drug's distribution

 It is estimated that the drug sales could reach an annual value of about 100 crore, in about 2-3 years
Bigul
28 Jun 2024

Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release titled as "Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India" is being released by the Company.
Bigul
27 Jun 2024

Orchid Pharma Ltd - 524372 - Closure of Trading Window

 Intimation for closure of Trading Window for the Quarter/period ending on June 30, 2024
Bigul
16 Jun 2024

Orchid Pharma blossoms with new blockbuster drug

 The pharma company's India-discovered drug Enmetazobactum, the first to receive US FDA approval, will help it flower with strength
Bigul
14 Jun 2024

Orchid Pharma Ltd - 524372 - Investor Roadshows Scheduled To Be Held On June 18 And 19, 2024

 The Company will be participating in Investor Road Show Scheduled to be held on June 18 and 19, 2024.
Bigul
13 Jun 2024

Orchid to launch Enmetazobactum by next quarter

 Seeks permission from Tamil Nadu government to manufacture the drug at its Chennai plant
06 Jun 2024

Orchid Pharma Gets Green Light From DCGI For New Antibiotic Drug

 Orchid Pharma receives approval from DCGI to manufacture new antibiotic drug for complicated urinary tract infections.
Bigul
06 Jun 2024

Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release- Orchid Pharma receives DCGI approval for its first invented and made-in-antibiotic Drug combination of Cefepime and Enmetazobactam (NCE).
Bigul
04 Jun 2024

Orchid Pharma Ltd - 524372 - Investor Roadshows Scheduled To Be Held On June 05 And 06, 2024

 Company will participate in Investor Roadshow scheduled to be held on June 05 and June 06, 2024
See all News

FAQs

The latest market price of Orchid Pharma Ltd. on NSE was Rs. 1134.35 as of today.

The opening share price of Orchid Pharma Ltd. was Rs. 1145.00 as of today.

The 52-week high share price of Orchid Pharma Ltd. was Rs. 1360.00.

The 52 week low share price of Orchid Pharma Ltd. was Rs. 432.00.

Orchid Pharma Ltd. has a market cap of Rs. 5753.30 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Orchid Pharma Ltd. is 0.60. Please refer to the Fundamentals section for further details.

The operating revenue for Orchid Pharma Ltd. in the last FY was Rs.  819.37 crore. Please refer to the Financials section for further details.

The Net Profit for Orchid Pharma Ltd. in the last FY was Rs. 91.60 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Orchid Pharma Ltd. was on 2012-09-13 for Rs. 3 per share. According to today’s share price, the dividend yield of Orchid Pharma Ltd. stands at 0.00. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Orchid Pharma Ltd. was as of 2005-09-15. The bonus ratio declared in this issue was 1:2. Please refer to the Corporate Actions section for further details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Orchid Pharma Ltd..

Close

Let's Open Free Demat Account